<DOC>
	<DOC>NCT02033590</DOC>
	<brief_summary>The objective of this study is to prospectively observe clinical and economic outcomes with the use of SERI® in direct-to-implant breast reconstruction.</brief_summary>
	<brief_title>Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction</brief_title>
	<detailed_description />
	<criteria>Be willing to undergo immediate breast reconstruction following a skinsparing or nipple sparing mastectomy with healthy, sufficiently thick, wellvascularized skin flaps, and the implantation of SERI® Surgical Scaffold and breast implant Be female, between 18 and 65 years of age at the time of enrollment Have undergone prior radiation treatment on the study breast(s) and/or is preoperatively evaluated to require radiation treatment to the study breast(s) during the course of the study Have undergone a skin reducing mastectomy Have a BMI that is &lt;17 or ≥ 30 Predicted implant weight more than 500 grams Have a known allergy to silk Have an abscess or active infection at any location within one month prior to surgery Be pregnant, lactating, or if of childbearing potential, be unwilling to use contraceptive methods and avoid pregnancy throughout the study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>